Literature DB >> 26553522

Spontaneous Pathology and Routine Clinical Pathology Parameters in Aging Beagle Dogs: A Comparison With Adolescent and Young Adults.

J Barnes1, P Cotton1, S Robinson1, M Jacobsen2.   

Abstract

AstraZeneca ran a bespoke study to generate age-matched clinical pathology and histopathology data from a cohort of Beagle dogs aged between 25 and 37 months to support the use of these older animals in routine preclinical toxicology studies. As the upper age range of Beagle dogs routinely used in toxicology studies does not normally exceed 24 months, there is an absence of appropriate age-matched historical control data. The generation of such data was crucial to understand whether age-related differences in spontaneous findings might confound the interpretation of toxicology study data. While the majority of the histopathology findings in all the older dogs occurred at a similar prevalence as those expected in young adult dogs (<24 months), a number of differences were observed in the thymus (involution), bone marrow (increased adiposity), testes (degenerative changes), and lung (fibrosis, pigment and alveolar hyperplasia) that could be misinterpreted as a test article effect. Minor differences in some clinical pathology values (hemoglobin, alkaline phosphatase, absolute reticulocytes) were of a small magnitude and considered unlikely to affect the interpretation of study data.
© The Author(s) 2015.

Entities:  

Keywords:  aging; background lesions; beagle; clinical pathology; dog; histopathology; incidental findings; toxicology studies

Mesh:

Year:  2015        PMID: 26553522     DOI: 10.1177/0300985815610390

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  1 in total

1.  Cystic thymic degeneration with pseudoepitheliomatous hyperplasia in a Beagle puppy: an idiopathic lesion?

Authors:  Giulia Moretti; Monica Sforna; Domenico Caivano; Luca Mechelli; Antonello Bufalari; Ilaria Porcellato
Journal:  J Vet Diagn Invest       Date:  2020-04-10       Impact factor: 1.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.